Replication-deficient Simian Adenoviral Vector Vaccine


Research Institution

University of Oxford


We have developed a replication-deficient simian adenoviral vector vaccine expressing the SARS-CoV-2 surface Spike protein (ChAdOx1 nCoV-19). Small scale GMP manufacture is in progress (at UOXF), with Phase I/II trials in Oxford due to initiate shortly. Process Development work for larger scale manufacture is also in progress.

Research Team

Andrew Pollard
Professor of Paediatric Infection and Immunity
University of Oxford
Adrian Hill
Professor of Human Genetics
University of Oxford
Sarah Gilbert
Head of Vaccine Development
University of Oxford
Teresa Lambe
Senior Scientist
University of Oxford
Sandy Douglas
Head of Sporozoite-targeting Malaria & Rabies Vaccines
University of Oxford

Project Details

Funding Sources

Funding in place from UKRI, NIHR, CEPI and CIFMS (CAMS Innovation fund for medical sciences).

Project Phases

  1. Phase I/II testing for safety and immunogenicity,
  2. Phase II/III testing for efficacy.
  3. Large scale GMP manufacture
  4. Additional funding will be required for full programme to be carried out

Planned Time to Trials

< 6 Months


Hover for more information.
Expert Advice

Get In Touch

Directly connect with the responsible researchers by sending a message.
Thank you! Your message has been received and will be forwarded to the research team!
Oops! Something went wrong while submitting the form.